Nature's Sunshine Names CFO, Posts Q2 Results, and Trims Full-Year Outlook
NATR sits 26% above its 52-week low of $12.973.
Summary
Nature's Sunshine reported Q2 2026 earnings with sales up 2% to $117 million but cut full-year guidance, citing FX headwinds and China softness. The company also named Ruth Perkins as its new CFO, effective September 1.
Key Events · Earnings and Guidance · NATR
-
Full-Year Guidance Lowered
Management cut 2026 net sales guidance to $490-$500 million from $500-$515 million and adjusted EBITDA to $48-$52 million from $50-$54 million, citing a stronger U.S. dollar and recent softness in China.
-
Q2 Earnings Mixed
Net sales rose 2% to $117.0 million (4% constant currency), gross margin expanded 194 bps to 73.7%, but GAAP EPS fell to $0.19 from $0.28 a year ago due to higher SG&A and lower other income.
-
New CFO Appointed
Ruth Perkins, formerly SVP at Estée Lauder, will become EVP and CFO effective September 1, 2026, with a $575,000 base salary, 70% target bonus, and $1.65 million in equity awards. She fills the vacancy left by the prior CFO's resignation in May 2026.
-
Balance Sheet Remains Strong
Cash and equivalents stood at $82.5 million with zero debt as of June 30, 2026, though operating cash flow was negative $1.0 million in the first half of 2026.
Analysis · NATR · Life Sciences
A mixed quarter for Nature's Sunshine: sales edged up 2% to $117 million and gross margins improved, yet GAAP EPS slipped to $0.19 from $0.28 a year ago. The bigger story is management's decision to lower full-year revenue and adjusted EBITDA guidance, pointing to a stronger dollar and softness in China. Effective September 1, Ruth Perkins steps in as CFO, filling the gap left by the prior CFO's May resignation. Her package includes a $575,000 salary, a 70% target bonus, and $1.65 million in equity awards. The guidance cut dominates the narrative—it resets expectations lower and will likely weigh on the stock.
At the time of this filing, NATR was trading at $16.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $357.7M. The 52-week trading range was $12.97 to $28.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.